CV risk lower with metformin in T2DM and reduced kidney function
(PHYSorg.com Medicine & Health)

(HealthDay)-Treatment with metformin versus sulfonylureas is associated with a reduced risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes and reduced kidney function, according to a study published online Sept. 19 in the Journal of the American Medical Association to coincide with the annual meeting of the European Association for the Study of Diabetes, held from Sept. 16 to 20 in Barcelona, Spain.